Synopsis: Brett Hall, Ph.D., is the CSO of Immuneering, a public, clinical-stage oncology company dedicated to developing medicines for broad populations of cancer patients by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Brett talks about his background in the military targeting nuclear missiles prior to becoming a scientist and some of the commonalities between working in the military and pharma/biotech. He shares his thoughts on AI and machine learning in drug development. He talks about Immuneering’s disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its pipeline. Finally, he discusses their focus on oncology and providing potential treatments for patients with advanced solid tumors. Biography: Brett Hall, Ph.D. has served as Chief Scientific Officer of Immuneering since November 2019. He also served as the Founder and Chairman of the board of directors of BioArkive, Inc., or BioArkive, a privately held biotechnology services company from January 2019 until December 2021. Prior to joining Immuneering, Dr. Hall served as the Chief Executive Officer of Asellus Therapeutics, LLC from July 2015 until May 2018. Dr. Hall served in roles of increasing responsibility with Johnson & Johnson from November 2008 until July 2014, culminating in his role as the Head of Biomarkers of the Hematologic Disease Area Stronghold, where he led translational efforts for Sylvant® and Imbruvica® through clinical development. Subsequently, he served as the Head of Translational Medicine of Oncology at Medimmune, LLC, the biologics division of AstraZeneca Pharmaceuticals LP, from July 2014 until July 2015, before transitioning to executive discovery roles in biotechnology. He has extensive drug development and leadership experience ranging from early drug discovery through translational clinical sciences, including multiple drug registrations. Dr. Hall has extensively published in the areas of tumor microenvironment (TME) and translational sciences, and holds multiple patents for drug pharmacology and discovery. He was also a tenure-track Assistant Professor at Ohio State University where his laboratory focused on the development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers. Prior to Dr. Hall’s career in life sciences, he served in the United States Air Force and worked as an investment banker. Dr. Hall received his B.S. in biochemistry from Ohio State University, his Ph.D. in immunology and cancer biology from West Virginia University, and completed his post-doctoral fellowship in cancer cell epigenetics at St. Jude Children’s Research Hospital.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related